Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232563 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL2232567 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL2232577 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL27770642 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL8437481 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL6691321 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL1520430 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL20279659 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL14366321 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL77922 | 0.78 | ALDH1A1 (0.62) | ALDH1A1TSHRHTTHPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136521-A1 | Method for Selectively Depleting Hypoxic Cells | GENETIX PHARMACEUTICALS , INC. (US) | 2009-05-28 | — | — | US | claimed |
| EP-1931769-A2 | METHOD FOR SELECTIVELY DEPLETING HYPOXIC CELLS | Genetix Pharmaceuticals Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007041546-A2 | METHOD FOR SELECTIVELY DEPLETING HYPOXIC CELLS | GENETIX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-11262362-B2 | 2-hydroxyglutarate as a biomarker for chronic hypoxia | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-03-01 | — | — | US | disclosed |
| EP-2350664-B1 | TREATMENT OF CANCER USING THE HYPOXIA ACTIVATED PRODRUG TH-302 IN COMBINATION WITH DOCETAXEL OR PEMETREXED | IMMUNOGENESIS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2780700-B1 | 2-HYDROXYGLUTARATE AS A BIOMARKER FOR CHRONIC HYPOXIA | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20160144002-A1 | Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors | TERMAN DAVID S (US) | 2016-05-26 | — | — | US | disclosed |
| US-9278124-B2 | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods | HALOZYME, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160033533-A1 | 2-HYDROXYGLUTARATE AS A BIOMARKER FOR CHRONIC HYPOXIA | SLOAN KETTERING INST CANCER (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150258125-A1 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150037297-A1 | Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors | TERMAN DAVID S (US) | 2015-02-05 | — | — | US | disclosed |
| US-20120195869-A1 | Sickled Erythrocytes with Anti-tumor Agents Induce Tumor Vaso-occlusion and Tumoricidal Effects | TERMAN DAVID S (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2350664-A1 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100203024-A1 | Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy | TERMAN DAVID S | 2010-08-12 | — | — | US | disclosed |
| US-20100158871-A1 | Sickled erythrocytes with antitumor molecules induce tumoricidal effects | Terman, David Stephen (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010048330-A1 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20090136521-A1 | Method for Selectively Depleting Hypoxic Cells | GENETIX PHARMACEUTICALS , INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1931769-A2 | METHOD FOR SELECTIVELY DEPLETING HYPOXIC CELLS | Genetix Pharmaceuticals Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007143451-A2 | TARGETED DELIVERY OF ONCOLYTIC VIRUSES, ANTI-TUMOR PROTEINS, PLASMIDS, TOXINS, HEMOLYSINS & CHEMOTHERAPY | TERMAN DAVID S (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007041546-A2 | METHOD FOR SELECTIVELY DEPLETING HYPOXIC CELLS | GENETIX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258125-A1 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS | HIF1AN, HIF1A, EGLN3 | ALDH1A1 87/4885TSHR 918/4885HTT 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.